Annovis Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANVS New York 2830 www.annovisbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annovis Bio, Inc.

Annovis Bio granted U.S. patent covering buntanetap - Jan 15th, 2025 1:11 pm
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - Jan 14th, 2025 1:00 pm
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway - Jan 7th, 2025 1:00 pm
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace - Dec 5th, 2024 1:30 pm
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Nov 25th, 2024 1:00 pm
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - Nov 12th, 2024 1:00 pm
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - Nov 11th, 2024 1:00 pm
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Nov 11th, 2024 11:20 am
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - Nov 7th, 2024 1:00 pm
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - Oct 31st, 2024 12:00 pm
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - Oct 22nd, 2024 12:00 pm
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Oct 17th, 2024 2:52 pm
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - Oct 15th, 2024 12:00 pm
Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - Oct 3rd, 2024 12:30 pm
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - Oct 2nd, 2024 12:30 pm
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - Sep 30th, 2024 12:00 pm
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - Sep 5th, 2024 12:00 pm
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders - Aug 22nd, 2024 11:10 am
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update - Aug 15th, 2024 11:00 am
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated - Aug 9th, 2024 2:31 pm